Previous Close | 22.77 |
Open | 23.63 |
Bid | 23.37 x 100 |
Ask | 23.49 x 300 |
Day's Range | 23.31 - 23.99 |
52 Week Range | 14.89 - 32.53 |
Volume | |
Avg. Volume | 737,758 |
Market Cap | 2.13B |
Beta (5Y Monthly) | 1.06 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Rocket Pharmaceuticals (RCKT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. The fund advanced 8.92% (Institutional Shares) in the quarter compared to an 8.52% gain for the Russell 3000 Health Care Index (benchmark) and a 10.56% increase for the S&P […]
The EMA accepts Rocket's (RCKT) regulatory submission seeking approval for RP-L102, a gene therapy for a rare genetic disorder called fanconi anemia that affects the bone marrow.